CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics
Beside cardiovascular diseases, malignant tumours take
the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Novel catalyst for charge separation in photocatalytic water splitting
A research team led by Prof. JIANG Hailong, Prof. LUO Yi, and Prof. JIANG Jun from the University of Science and Technology of China (USTC) discovered a metal-organic framework (MOF)…
Finding a missing piece for neurodegenerative disease research
Research led by the University of Michigan has provided compelling evidence that could solve a fundamental mystery in the makeup of fibrils that play a role in Alzheimer’s, Parkinson’s and…
BESSY II: New procedure for better thermoplastics
Thermoplastic blends, produced by a new process, have better resilience. Now, experiments at the IRIS beamline show, why: nanocrystalline layers increase their performance. Bio-based thermoplastics are produced from renewable organic…